Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P, Lee LC, Han M, Matthews JD, Jahangiri L, Schlederer M, Manners E, Sorby-Adams A, Kaggie J, Trigg RM, Steel C, Hare L, James ER, Prokoph N, Ducray SP, Merkel O, Rifatbegovic F, Luo J, Taschner-Mandl S, Kenner L, Burke GAA, Turner SD.
Pucci P, et al. Among authors: lee lc.
Nat Commun. 2024 Apr 23;15(1):3422. doi: 10.1038/s41467-024-47771-x.
Nat Commun. 2024.
PMID: 38653965
Free PMC article.